Polymyositis (PM) is a rare autoimmune, at times considered paraneoplastic, inflammatory condition characterised by proximal muscle weakness. It is considered a form of idiopathic inflammatory myopathy (IIM). The condition is closely related to dermatomyositis, and the term “polymyositis” is applied when the condition spares the skin.
It principally affects the skeletal system but can also affect other organ systems, such as the lungs (see polymyositis - lung involvement).
There are several forms of the disease. The most common form affects whose in their fourth decade. There is a recognised female predilection (~2F:1M).
Polymyositis usually presents insidiously in a period of a few months with symmetrical painless muscular weakness with no cutaneous manifestations (c.f. dermatomyositis). Myalgia has been reported in less than one-third of the patients.
Muscle involvement is usually symmetric, but not necessarily evenly distributed.
MRI has been used for diagnosis aid, follow-up, and to identify the best area for muscular biopsy.
- T2/STIR: affected regions during active disease have high signal intensity, reflecting muscle oedema
Other features, in a chronic phase, would include 3:
- fatty infiltration of muscles
- muscle calcification
Treatment and prognosis
This condition usually tends to be progressive.
On MRI there is a broad differential:
Some differentials to consider include:
- usually, will not involve all the muscular compartments and will not present with a relatively symmetrical bilateral pattern
inclusion body myositis
- usually involving patients over 50 years
- collagen vascular diseases (e.g. systemic lupus erythematosus, Sjogren syndrome, and rheumatoid arthritis)
- has a more focal, sometimes nodular, myositis
drug-induced myositis (e.g. statins, antiretroviral drugs used in HIV treatment)
- reversible after discontinuation of the medication
muscular dystrophy (e.g. Duchenne)
- muscles evolves from an oedematous phase to become atrophic
- there is no associated skin and subcutaneous oedema
- 1. O'Connell MJ, Powell T, Brennan D et-al. Whole-body MR imaging in the diagnosis of polymyositis. AJR Am J Roentgenol. 2002;179 (4): 967-71. doi:10.2214/ajr.179.4.1790967 - Pubmed citation
- 2. Akira M, Hara H, Sakatani M. Interstitial lung disease in association with polymyositis-dermatomyositis: long-term follow-up CT evaluation in seven patients. Radiology. 1999;210 (2): 333-8. doi:10.1148/radiology.210.2.r99ja15333 - Pubmed citation
- 3. Tomasová Studynková J, Charvát F, Jarosová K et-al. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford). 2007;46 (7): 1174-9. doi:10.1093/rheumatology/kem088 - Pubmed citation
- 4. Dion E, Cherin P, Payan C et-al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J. Rheumatol. 2002;29 (9): 1897-906. J. Rheumatol. (abstract) - Pubmed citation